Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Agid
Y
Y
INSERM U 289 & Fédération de Neurologie, Hôpital de la Salpêtrière-47, Paris, France.
Ahlskog
E
E
Albanese
A
A
Calne
D
D
Chase
T
T
De Yebenes
J
J
Factor
S
S
Fahn
S
S
Gershanik
O
O
Goetz
C
C
Koller
W
W
Kurth
M
M
Lang
A
A
Lees
A
A
Lewitt
P
P
Marsden
D
D
Melamed
E
E
Michel
P P
PP
Mizuno
Y
Y
Obeso
J
J
Oertel
W
W
Olanow
W
W
Poewe
W
W
Pollak
P
P
Tolosa
E
E
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001921:Brain / Q000187:drug effects; D016923:Cell Death / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D007980:Levodopa